He oversees a variety of the research projects, including molecular genetics related to human fertilization and development of the early embryo, research into structural and numerical chromosome abnormalities. He supervises research related to new freezing technologies for spermatozoa, eggs and embryos, and microsurgical studies aimed at developing tools for clinical evaluation and therapy for reproductive cells and embryos.
Dr. Cohen has been actively involved in treating infertile couples in assisted reproductive technologies since 1976. In 1982, after earning a Ph.D. in Reproductive Physiology from the Erasmus University of Rotterdam, he went to England and joined the team of Dr. Edwards and Steptoe, who were responsible for the first ever IVF birth. He was the first to culture human embryos on a layer media and oil. and was the first to apply micromanipulation techniques on eggs, sperm, and embryos. This led to the development and application of several methods that are now routine procedures worldwide.
Dr. Cohen has published more than 200 scientific papers and is a frequent lecturer, both nationally and internationally on his team's work and the field of reproductive science.
Galileo Research Laboratories
Galileo Research Laboratories is an organization created by world-renowned specialists in reproductive science and molecular genetics. In founding the Galileo laboratories, these individuals have joined together to stimulate progress in medical research, particularly in the areas of reproductive medicine, gametogenesis, human pre-implantation embryology and genetics. The research that Galileo promotes will enhance the understanding of human reproduction and the origin of human disease and facilitate development of treatment modalities that can lead to the eradication of infertility and certain genetic diseases.
The advancement of assisted reproductive technology (ART), including preimplantation genetic diagnosis (PGD) not only benefits the treatment of infertility and genetic disease. This research also shows great promise in elucidating fundamental aspects of biology with much wider clinical and scientific significance. Since government funding, and philanthropic and other support for research in these areas is limited, Galileo serves as a particularly important source of financial and scientific support for these efforts.
Galileo operates a number of research laboratories and supports affiliated Galileo Centers worldwide working towards the common goals of achieving excellence, promoting the exchange of information, advancing reproductive science and assisting infertile patients. Galileo strives to attract outstanding scientists and provide support wherever it can to clinical teams in order to optimize periormance and introduce new cutting edge technology.